Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

IL-4 fusion toxin effective in preclinical Kaposi's sarcoma models

July 2, 1999

Avax to launch M-Vax in Australia, forms joint venture for AC Vaccine

July 2, 1999

Transgene initiates phase I trial of malignant melanoma product

June 25, 1999

ImmunoGen receives second milestone payment for anticancer prodrug from SmithKline Beecham

June 22, 1999

Corixa teams up with Japan Tobacco on lung cancer vaccine research

June 21, 1999

Seven preclinical studies demonstrate antitumor activity of NovoMAb-G2

June 16, 1999

Campath-1H trial results presented in Barcelona

June 15, 1999

Follow-up data presented for Bexxar cancer therapy

June 15, 1999

Theragyn improves long-term survival in ovarian cancer patients

June 14, 1999

Data from phase I/II study of NBI-3001 presented at German Society of Neurosurgery

June 11, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...